Global PEGylated Proteins Market Size, Share & Industry Trends Analysis Report By Product & Services, By Type (Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin), By End-user, By Application, By Regional Outlook and Forecast,

Global PEGylated Proteins Market Size, Share & Industry Trends Analysis Report By Product & Services, By Type (Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin), By End-user, By Application, By Regional Outlook and Forecast, 2022 - 2028

The Global PEGylated Proteins Market size is expected to reach $2.1 billion by 2028, rising at a market growth of 11.3% CAGR during the forecast period.

PEGylation is covalently and non-covalently connecting polyethylene glycol polymer chains to molecules, such as treatments, medications, or vesicles. The industry is expected to expand significantly throughout the anticipated time period, mainly due to increased PEGylation demand, a rise in the occurrence of chronic diseases, and the availability of effective new therapeutic options.

PEGylated chemicals also have certain extra advantages that support the growth of the sector, such as improved proteolytic defense, a longer half-life, decreased toxicity, and reduced immunogenicity. Because of their great biological activity and excellent selectivity, protein medicines have emerged as significant modern pharmacological products.

In combination with protein inactive necessary groups, polyethylene glycol (PEG), a type of non-toxic, high hydrophilic macromolecule polymer, increases the relative molecular mass of the protein drugs, causing some changes to the antigenic determinant that is covered on the surface of the charged property. Both domestically and internationally, there has been noticeable interest in the utilization of PEGylated technology in protein medicines.

A wide range of PEGylated medications on the market has completely established both their therapeutic and commercial usefulness. The preference for protein-based pharmaceuticals over non-protein-based drugs is increasing, and PEGylation's enhancement of protein stability and circulation half-life is anticipated to drive the PEGylated Protein Industry's expansion throughout the projection period.

The key driver of the industry's growth is the increasing prevalence of chronic conditions like cancer, kidney illness, and rheumatoid arthritis. For instance, according to estimations from the IARC (International Agency for Research on Cancer), there will be 19.3 million new cases of cancer and 10.3 million cancer deaths globally in 2020.

COVID-19 Impact Analysis

The COVID-19 pandemic was beneficial to the sector. The government and major players increased their investments in the creation of cutting-edge medication candidates for COVID-19 prevention. Increased research and development for new vaccines, diagnostics, and the repurposing of current medicines were closely linked to an increase in investments. For instance, Zydus Cadila, an Indian pharmaceutical company, acquired an Emergency Use Approval (EUA) in April 2021 to use its PEGylated Interferon alpha 2b existing medication to treat COVID-19 patients with mild instances. The medicine had previously been approved to treat Hepatitis B, but after extensive study and clinical trials across India, it was repurposed for COVID-19.

Market Growth Factors

Pegylated proteins are being used more often and in a variety of applications.

The development of more stable and non-immunogenic medicines is made possible by major improvements in PEGylated protein processes, which are predicted to accelerate the growth of the worldwide PEGylated protein market. Given the huge increase in cancer patients, the approach has strong applicability in the treatment of cancer. World Health Organization (WHO) estimates that 9.6 million individuals worldwide lost their lives to cancer in 2018. After being PEGylated, the protein from the CCN family can be employed in the treatment of blood cancer.

The Rising Rate Of Cancer Worldwide

The second-leading cause of death, cancer, is responsible for a significant fraction of all fatalities. Wealthy countries have a substantially higher cancer rate than developing ones. It is anticipated that recognized risk factors will be increasingly prominent in these developing nations due to population growth, aging, and a rise in known risk factors. Lung cancer is among the major cause of cancer-related death in men only in industrialized countries, while breast cancer is the major cause of cancer deaths in developing countries.

Market Restraining Factors

Isolation And Purification Challenges

Protein PEGylation is a complicated process that can be carried out in different ways, depending on the protein's makeup and the intended use. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Another crucial step is the purification of the PEGylated protein, which is mostly accomplished through chromatography and electrostatic interactions or molecular sizes. For conditions such as anemia, kidney illness, multiple sclerosis, hemophilia, and malignancies, a number of PEGylated medications are in use.

Product and Services Outlook

Based on the Product and Services, the market is divided into Consumables and Services. The market's substantial revenue share is displayed by the services sector. PEGylated Proteins services are available in both linear and branching formats and can be used with PEGs of various molecular weights. Peptides and proteins frequently have limitations on their capacity to be used therapeutically due to their chemical instability, quick blood circulation, and propensity to trigger an immune response.

Type Outlook

Based on the type, the market is divided into Colony-stimulating factors, Interferons, Erythropoietin, Recombinant factor VII, and Others. Erythropoietin is demonstrating the market's optimistic growth pace. The expansion of erythropoietin drugs is being driven by an increase in the prevalence of chronic diseases such as end-stage renal diseases, cancer, HIV, and neurological disorders. Drugs that mimic erythropoietin (EPO) can be used to treat severe anemia in people with cancer, HIV, and renal disease.

Application Outlook

Based on Application, the market is divided into Cancer, Autoimmune diseases, Hepatitis, Multiple sclerosis, Hemophilia, Gastrointestinal disorders, and Others. The market is showing a promising growth rate for the other segments. Protein drug delivery and other disorders are included in the others section. The market for PEGylated Proteins is anticipated to grow as a result of the rising frequency of chronic disorders. PEGylated proteins improve a drug's action relative to a standard drug by increasing the stability of the substance in the body.

End-User Outlook

Based on the end-user, the market is divided into Pharmaceutical and biotechnology businesses, Contract research organizations, and Academic & research institutes. The significant revenue share in the industry was accounted for by Contract Research Organizations (CROs). CROs are currently more prevalent as a result of the rising demand for outside help with contract research and the creation of pharmaceuticals. Additionally, due to the hassle-free process and FDA clearance, the biotechnology and pharmaceutical industries now rely on CROs for support.

Regional Outlook

Based on geography, the market is categorized into North America, Europe, Asia Pacific, and LAMEA. In 2021, North America led the market and held the largest share. The region's healthcare infrastructure has grown as a result of the incidence of ailments and diseases, chronic conditions, and population awareness of modern therapies. The increase in funding and grants for biologics-based research activities is facilitated by the presence of improved infrastructure and better economic conditions.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.

Strategies Deployed in PEGylated Proteins Market

Nov-2022: Thermo Fisher Scientific completed the acquisition of The Binding Site Group, a UK-based specialist protein company providing diagnostic products and instruments to clinicians and laboratories globally. This acquisition broadened Thermo's existing specialty diagnostics portfolio.

Aug-2022: Merck Group, the parent organization of Merck Millipore took over the Chemical division of Mecaro, a company focused on manufacturing heater blocks and chemical precursors for semiconductors. This acquisition enhances Merck's portfolio of semiconductor solutions.

Apr-2022: Thermo Fisher Scientific launched GMP-manufactured Gibco CTS TrueCut Cas9 protein. The product enhances Thermo's existing genome editing solutions and provides support to scientists developing personalized CAR T-cell therapeutics.

Mar-2022: Thermo Fisher took over Max Analytical, a chemical instrumentation company providing FTIR-based gas analytical solutions. The acquisition broadened Thermo's FTIR instrument, software, and service offerings.

Jan-2022: Thermo Fisher Scientific announced the acquisition of PeproTech, a provider of bioscience reagents. The acquisition complemented Thermo's bioscience business and enabled them to deliver better services to its pharma and biotech customers.

Dec-2021: Thermo Fisher acquired PPD, a pharmaceutical firm offering clinical research and laboratory services. The addition of PPD's clinical research services enables Thermo to advance its work in launching life-changing therapies to market.

Oct-2021: Thermo Fisher Scientific collaborated with 3M Health Car for maximizing process scalability and efficiency in commercial therapeutic manufacturing. The collaboration integrates Thermo's HyPerforma Single-Use Bioreactor Systems and 3M's Harvest RC providing premium solutions to advance manufacturing capacity to produce therapeutics.

Jan-2021: Thermo Fisher completed the acquisition of Mesa Biotech, a healthcare test and data company providing the molecular diagnostic test. This acquisition complemented Thermo's existing test services and helped Thermo cater to the increasing demand for COVID-related testing.

Scope of the Study

Market Segments covered in the Report:

By Product & Services

  • Consumables
  • Services
By Type
  • Colony-stimulating Factor
  • Interferons
  • Recombinant Factor VII
  • Erythropoietin
  • Others
By End-user
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
By Application
  • Cancer
  • Autoimmune Diseases
  • Hepatitis
  • Multiple Sclerosis
  • Hemophilia
  • Gastrointestinal Disorders
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Merck Millipore (Merck KGaA)
  • Thermo Fisher Scientific, Inc.
  • NOF Corporation
  • JenKem Technology Co. Ltd.
  • Creative PEGworks
  • Celares GmbH
  • Quanta BioDesign, Ltd.
  • Biomatrik, Inc.
  • Iris Biotech GmbH
  • Laysan Bio, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global PEGylated Proteins Market, by Product & Services
1.4.2 Global PEGylated Proteins Market, by Type
1.4.3 Global PEGylated Proteins Market, by End-user
1.4.4 Global PEGylated Proteins Market, by Application
1.4.5 Global PEGylated Proteins Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in PEGylated Proteins Market
Chapter 4. Global PEGylated Proteins Market by Product & Services
4.1 Global Consumables Market by Region
4.2 Global Services Market by Region
Chapter 5. Global PEGylated Proteins Market by Type
5.1 Global Colony-stimulating Factor Market by Region
5.2 Global Interferons Market by Region
5.3 Global Recombinant Factor VII Market by Region
5.4 Global Erythropoietin Market by Region
5.5 Global Others Market by Region
Chapter 6. Global PEGylated Proteins Market by End-user
6.1 Global Pharmaceutical & Biotechnology Companies Market by Region
6.2 Global Contract Research Organizations (CROs) Market by Region
6.3 Global Academic & Research Institutes Market by Region
Chapter 7. Global PEGylated Proteins Market by Application
7.1 Global Cancer Market by Region
7.2 Global Autoimmune Diseases Market by Region
7.3 Global Hepatitis Market by Region
7.4 Global Multiple Sclerosis Market by Region
7.5 Global Hemophilia Market by Region
7.6 Global Gastrointestinal Disorders Market by Region
7.7 Global Others Market by Region
Chapter 8. Global PEGylated Proteins Market by Region
8.1 North America PEGylated Proteins Market
8.1.1 North America PEGylated Proteins Market by Product & Services
8.1.1.1 North America Consumables Market by Country
8.1.1.2 North America Services Market by Country
8.1.2 North America PEGylated Proteins Market by Type
8.1.2.1 North America Colony-stimulating Factor Market by Country
8.1.2.2 North America Interferons Market by Country
8.1.2.3 North America Recombinant Factor VII Market by Country
8.1.2.4 North America Erythropoietin Market by Country
8.1.2.5 North America Others Market by Country
8.1.3 North America PEGylated Proteins Market by End-user
8.1.3.1 North America Pharmaceutical & Biotechnology Companies Market by Country
8.1.3.2 North America Contract Research Organizations (CROs) Market by Country
8.1.3.3 North America Academic & Research Institutes Market by Country
8.1.4 North America PEGylated Proteins Market by Application
8.1.4.1 North America Cancer Market by Country
8.1.4.2 North America Autoimmune Diseases Market by Country
8.1.4.3 North America Hepatitis Market by Country
8.1.4.4 North America Multiple Sclerosis Market by Country
8.1.4.5 North America Hemophilia Market by Country
8.1.4.6 North America Gastrointestinal Disorders Market by Country
8.1.4.7 North America Others Market by Country
8.1.5 North America PEGylated Proteins Market by Country
8.1.5.1 US PEGylated Proteins Market
8.1.5.1.1 US PEGylated Proteins Market by Product & Services
8.1.5.1.2 US PEGylated Proteins Market by Type
8.1.5.1.3 US PEGylated Proteins Market by End-user
8.1.5.1.4 US PEGylated Proteins Market by Application
8.1.5.2 Canada PEGylated Proteins Market
8.1.5.2.1 Canada PEGylated Proteins Market by Product & Services
8.1.5.2.2 Canada PEGylated Proteins Market by Type
8.1.5.2.3 Canada PEGylated Proteins Market by End-user
8.1.5.2.4 Canada PEGylated Proteins Market by Application
8.1.5.3 Mexico PEGylated Proteins Market
8.1.5.3.1 Mexico PEGylated Proteins Market by Product & Services
8.1.5.3.2 Mexico PEGylated Proteins Market by Type
8.1.5.3.3 Mexico PEGylated Proteins Market by End-user
8.1.5.3.4 Mexico PEGylated Proteins Market by Application
8.1.5.4 Rest of North America PEGylated Proteins Market
8.1.5.4.1 Rest of North America PEGylated Proteins Market by Product & Services
8.1.5.4.2 Rest of North America PEGylated Proteins Market by Type
8.1.5.4.3 Rest of North America PEGylated Proteins Market by End-user
8.1.5.4.4 Rest of North America PEGylated Proteins Market by Application
8.2 Europe PEGylated Proteins Market
8.2.1 Europe PEGylated Proteins Market by Product & Services
8.2.1.1 Europe Consumables Market by Country
8.2.1.2 Europe Services Market by Country
8.2.2 Europe PEGylated Proteins Market by Type
8.2.2.1 Europe Colony-stimulating Factor Market by Country
8.2.2.2 Europe Interferons Market by Country
8.2.2.3 Europe Recombinant Factor VII Market by Country
8.2.2.4 Europe Erythropoietin Market by Country
8.2.2.5 Europe Others Market by Country
8.2.3 Europe PEGylated Proteins Market by End-user
8.2.3.1 Europe Pharmaceutical & Biotechnology Companies Market by Country
8.2.3.2 Europe Contract Research Organizations (CROs) Market by Country
8.2.3.3 Europe Academic & Research Institutes Market by Country
8.2.4 Europe PEGylated Proteins Market by Application
8.2.4.1 Europe Cancer Market by Country
8.2.4.2 Europe Autoimmune Diseases Market by Country
8.2.4.3 Europe Hepatitis Market by Country
8.2.4.4 Europe Multiple Sclerosis Market by Country
8.2.4.5 Europe Hemophilia Market by Country
8.2.4.6 Europe Gastrointestinal Disorders Market by Country
8.2.4.7 Europe Others Market by Country
8.2.5 Europe PEGylated Proteins Market by Country
8.2.5.1 Germany PEGylated Proteins Market
8.2.5.1.1 Germany PEGylated Proteins Market by Product & Services
8.2.5.1.2 Germany PEGylated Proteins Market by Type
8.2.5.1.3 Germany PEGylated Proteins Market by End-user
8.2.5.1.4 Germany PEGylated Proteins Market by Application
8.2.5.2 UK PEGylated Proteins Market
8.2.5.2.1 UK PEGylated Proteins Market by Product & Services
8.2.5.2.2 UK PEGylated Proteins Market by Type
8.2.5.2.3 UK PEGylated Proteins Market by End-user
8.2.5.2.4 UK PEGylated Proteins Market by Application
8.2.5.3 France PEGylated Proteins Market
8.2.5.3.1 France PEGylated Proteins Market by Product & Services
8.2.5.3.2 France PEGylated Proteins Market by Type
8.2.5.3.3 France PEGylated Proteins Market by End-user
8.2.5.3.4 France PEGylated Proteins Market by Application
8.2.5.4 Russia PEGylated Proteins Market
8.2.5.4.1 Russia PEGylated Proteins Market by Product & Services
8.2.5.4.2 Russia PEGylated Proteins Market by Type
8.2.5.4.3 Russia PEGylated Proteins Market by End-user
8.2.5.4.4 Russia PEGylated Proteins Market by Application
8.2.5.5 Spain PEGylated Proteins Market
8.2.5.5.1 Spain PEGylated Proteins Market by Product & Services
8.2.5.5.2 Spain PEGylated Proteins Market by Type
8.2.5.5.3 Spain PEGylated Proteins Market by End-user
8.2.5.5.4 Spain PEGylated Proteins Market by Application
8.2.5.6 Italy PEGylated Proteins Market
8.2.5.6.1 Italy PEGylated Proteins Market by Product & Services
8.2.5.6.2 Italy PEGylated Proteins Market by Type
8.2.5.6.3 Italy PEGylated Proteins Market by End-user
8.2.5.6.4 Italy PEGylated Proteins Market by Application
8.2.5.7 Rest of Europe PEGylated Proteins Market
8.2.5.7.1 Rest of Europe PEGylated Proteins Market by Product & Services
8.2.5.7.2 Rest of Europe PEGylated Proteins Market by Type
8.2.5.7.3 Rest of Europe PEGylated Proteins Market by End-user
8.2.5.7.4 Rest of Europe PEGylated Proteins Market by Application
8.3 Asia Pacific PEGylated Proteins Market
8.3.1 Asia Pacific PEGylated Proteins Market by Product & Services
8.3.1.1 Asia Pacific Consumables Market by Country
8.3.1.2 Asia Pacific Services Market by Country
8.3.2 Asia Pacific PEGylated Proteins Market by Type
8.3.2.1 Asia Pacific Colony-stimulating Factor Market by Country
8.3.2.2 Asia Pacific Interferons Market by Country
8.3.2.3 Asia Pacific Recombinant Factor VII Market by Country
8.3.2.4 Asia Pacific Erythropoietin Market by Country
8.3.2.5 Asia Pacific Others Market by Country
8.3.3 Asia Pacific PEGylated Proteins Market by End-user
8.3.3.1 Asia Pacific Pharmaceutical & Biotechnology Companies Market by Country
8.3.3.2 Asia Pacific Contract Research Organizations (CROs) Market by Country
8.3.3.3 Asia Pacific Academic & Research Institutes Market by Country
8.3.4 Asia Pacific PEGylated Proteins Market by Application
8.3.4.1 Asia Pacific Cancer Market by Country
8.3.4.2 Asia Pacific Autoimmune Diseases Market by Country
8.3.4.3 Asia Pacific Hepatitis Market by Country
8.3.4.4 Asia Pacific Multiple Sclerosis Market by Country
8.3.4.5 Asia Pacific Hemophilia Market by Country
8.3.4.6 Asia Pacific Gastrointestinal Disorders Market by Country
8.3.4.7 Asia Pacific Others Market by Country
8.3.5 Asia Pacific PEGylated Proteins Market by Country
8.3.5.1 China PEGylated Proteins Market
8.3.5.1.1 China PEGylated Proteins Market by Product & Services
8.3.5.1.2 China PEGylated Proteins Market by Type
8.3.5.1.3 China PEGylated Proteins Market by End-user
8.3.5.1.4 China PEGylated Proteins Market by Application
8.3.5.2 Japan PEGylated Proteins Market
8.3.5.2.1 Japan PEGylated Proteins Market by Product & Services
8.3.5.2.2 Japan PEGylated Proteins Market by Type
8.3.5.2.3 Japan PEGylated Proteins Market by End-user
8.3.5.2.4 Japan PEGylated Proteins Market by Application
8.3.5.3 India PEGylated Proteins Market
8.3.5.3.1 India PEGylated Proteins Market by Product & Services
8.3.5.3.2 India PEGylated Proteins Market by Type
8.3.5.3.3 India PEGylated Proteins Market by End-user
8.3.5.3.4 India PEGylated Proteins Market by Application
8.3.5.4 South Korea PEGylated Proteins Market
8.3.5.4.1 South Korea PEGylated Proteins Market by Product & Services
8.3.5.4.2 South Korea PEGylated Proteins Market by Type
8.3.5.4.3 South Korea PEGylated Proteins Market by End-user
8.3.5.4.4 South Korea PEGylated Proteins Market by Application
8.3.5.5 Singapore PEGylated Proteins Market
8.3.5.5.1 Singapore PEGylated Proteins Market by Product & Services
8.3.5.5.2 Singapore PEGylated Proteins Market by Type
8.3.5.5.3 Singapore PEGylated Proteins Market by End-user
8.3.5.5.4 Singapore PEGylated Proteins Market by Application
8.3.5.6 Malaysia PEGylated Proteins Market
8.3.5.6.1 Malaysia PEGylated Proteins Market by Product & Services
8.3.5.6.2 Malaysia PEGylated Proteins Market by Type
8.3.5.6.3 Malaysia PEGylated Proteins Market by End-user
8.3.5.6.4 Malaysia PEGylated Proteins Market by Application
8.3.5.7 Rest of Asia Pacific PEGylated Proteins Market
8.3.5.7.1 Rest of Asia Pacific PEGylated Proteins Market by Product & Services
8.3.5.7.2 Rest of Asia Pacific PEGylated Proteins Market by Type
8.3.5.7.3 Rest of Asia Pacific PEGylated Proteins Market by End-user
8.3.5.7.4 Rest of Asia Pacific PEGylated Proteins Market by Application
8.4 LAMEA PEGylated Proteins Market
8.4.1 LAMEA PEGylated Proteins Market by Product & Services
8.4.1.1 LAMEA Consumables Market by Country
8.4.1.2 LAMEA Services Market by Country
8.4.2 LAMEA PEGylated Proteins Market by Type
8.4.2.1 LAMEA Colony-stimulating Factor Market by Country
8.4.2.2 LAMEA Interferons Market by Country
8.4.2.3 LAMEA Recombinant Factor VII Market by Country
8.4.2.4 LAMEA Erythropoietin Market by Country
8.4.2.5 LAMEA Others Market by Country
8.4.3 LAMEA PEGylated Proteins Market by End-user
8.4.3.1 LAMEA Pharmaceutical & Biotechnology Companies Market by Country
8.4.3.2 LAMEA Contract Research Organizations (CROs) Market by Country
8.4.3.3 LAMEA Academic & Research Institutes Market by Country
8.4.4 LAMEA PEGylated Proteins Market by Application
8.4.4.1 LAMEA Cancer Market by Country
8.4.4.2 LAMEA Autoimmune Diseases Market by Country
8.4.4.3 LAMEA Hepatitis Market by Country
8.4.4.4 LAMEA Multiple Sclerosis Market by Country
8.4.4.5 LAMEA Hemophilia Market by Country
8.4.4.6 LAMEA Gastrointestinal Disorders Market by Country
8.4.4.7 LAMEA Others Market by Country
8.4.5 LAMEA PEGylated Proteins Market by Country
8.4.5.1 Brazil PEGylated Proteins Market
8.4.5.1.1 Brazil PEGylated Proteins Market by Product & Services
8.4.5.1.2 Brazil PEGylated Proteins Market by Type
8.4.5.1.3 Brazil PEGylated Proteins Market by End-user
8.4.5.1.4 Brazil PEGylated Proteins Market by Application
8.4.5.2 Argentina PEGylated Proteins Market
8.4.5.2.1 Argentina PEGylated Proteins Market by Product & Services
8.4.5.2.2 Argentina PEGylated Proteins Market by Type
8.4.5.2.3 Argentina PEGylated Proteins Market by End-user
8.4.5.2.4 Argentina PEGylated Proteins Market by Application
8.4.5.3 UAE PEGylated Proteins Market
8.4.5.3.1 UAE PEGylated Proteins Market by Product & Services
8.4.5.3.2 UAE PEGylated Proteins Market by Type
8.4.5.3.3 UAE PEGylated Proteins Market by End-user
8.4.5.3.4 UAE PEGylated Proteins Market by Application
8.4.5.4 Saudi Arabia PEGylated Proteins Market
8.4.5.4.1 Saudi Arabia PEGylated Proteins Market by Product & Services
8.4.5.4.2 Saudi Arabia PEGylated Proteins Market by Type
8.4.5.4.3 Saudi Arabia PEGylated Proteins Market by End-user
8.4.5.4.4 Saudi Arabia PEGylated Proteins Market by Application
8.4.5.5 South Africa PEGylated Proteins Market
8.4.5.5.1 South Africa PEGylated Proteins Market by Product & Services
8.4.5.5.2 South Africa PEGylated Proteins Market by Type
8.4.5.5.3 South Africa PEGylated Proteins Market by End-user
8.4.5.5.4 South Africa PEGylated Proteins Market by Application
8.4.5.6 Nigeria PEGylated Proteins Market
8.4.5.6.1 Nigeria PEGylated Proteins Market by Product & Services
8.4.5.6.2 Nigeria PEGylated Proteins Market by Type
8.4.5.6.3 Nigeria PEGylated Proteins Market by End-user
8.4.5.6.4 Nigeria PEGylated Proteins Market by Application
8.4.5.7 Rest of LAMEA PEGylated Proteins Market
8.4.5.7.1 Rest of LAMEA PEGylated Proteins Market by Product & Services
8.4.5.7.2 Rest of LAMEA PEGylated Proteins Market by Type
8.4.5.7.3 Rest of LAMEA PEGylated Proteins Market by End-user
8.4.5.7.4 Rest of LAMEA PEGylated Proteins Market by Application
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Product Launches and Product Expansions:
9.1.5.3 Acquisition and Mergers:
9.2 Merck Millipore ( Merck Group)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 NOF Corporation
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expenses
9.4 Beijing Jiankai Technology Co., Ltd. (Jenkem)
9.4.1 Company Overview
9.5 Creative PEGworks
9.5.1 Company Overview
9.6 Celares GmbH
9.6.1 Company Overview
9.7 Quanta BioDesign Ltd.
9.7.1 Company Overview
9.8 Biomatrik, Inc.
9.8.1 Company Overview
9.9 Iris Biotech GmbH
9.9.1 Company Overview
9.10. Laysan Bio, Inc.
9.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings